Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00774930 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
A Phase 3 study, sponsored by Ipsen.
- Completed
- Registry status
- Phase 3
- Development phase
- 115
- Enrollment target
NCT00774930 is a Phase 3 study that has completed, run by Ipsen. The registered enrollment target is 115 participants.
The verdict
NCT00774930, a Phase 3 study, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 115 participants
- Enrollment target
Study Summary
The purpose of this study was to determine whether monthly deep subcutaneous (s.c.) injections of lanreotide Autogel (Somatuline Depot) were effective and safe in controlling diarrhoea and flushing by reducing the usage of s.c. short-acting octreotide as a rescue medication to control symptoms in subjects with carcinoid syndrome.
Interventions
- DRUG Placebo
- DRUG Lanreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2009-05 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00774930
The ClinicalTrials.gov registry entry for NCT00774930 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00774930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00774930 about?
NCT00774930 is a clinical study titled "An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome". The purpose of this study was to determine whether monthly deep subcutaneous (s.c.) injections of lanreotide Autogel (Somatuline Depot) were effective and safe in controlling diarrhoea and flushing by reducing the usage of s.c. short-acting octreotide as a rescue medication to control symptoms in su...
What is the current status of trial NCT00774930?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 115 participants. The study started on 2009-05. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00774930?
The interventions under investigation include: Placebo (DRUG), Lanreotide (DRUG).
Who is sponsoring clinical trial NCT00774930?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.